{"name":"Sherief Abd-Elsalam","slug":"sherief-abd-elsalam","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"FOLFERI","genericName":"FOLFERI","slug":"folferi","indication":"Other","status":"marketed"},{"name":"Coenzyme Q","genericName":"Coenzyme Q","slug":"coenzyme-q","indication":"Other","status":"marketed"},{"name":"Doxicycline","genericName":"Doxicycline","slug":"doxicycline","indication":"Other","status":"phase_3"},{"name":"Nigetella salivata","genericName":"Nigetella salivata","slug":"nigetella-salivata","indication":"Other","status":"phase_3"},{"name":"Pantoprazole high dose","genericName":"Pantoprazole high dose","slug":"pantoprazole-high-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Pantoprazole low dose","genericName":"Pantoprazole low dose","slug":"pantoprazole-low-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir","genericName":"Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir","slug":"sofosbuvir-and-ledipasvir-or-sofosbuvir-and-daklatasuvir","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Folfox with avastin","genericName":"Folfox with avastin","slug":"folfox-with-avastin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"CHOP Plus Famotidine","genericName":"CHOP Plus Famotidine","slug":"chop-plus-famotidine","indication":"Lymphoma (specific subtype under investigation in Phase 3)","status":"phase_3"},{"name":"CHOP Plus Lanzoprazole","genericName":"CHOP Plus Lanzoprazole","slug":"chop-plus-lanzoprazole","indication":"Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori","status":"phase_3"},{"name":"Classic treatment","genericName":"Classic treatment","slug":"classic-treatment","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Folferi and celecoxib","genericName":"Folferi and celecoxib","slug":"folferi-and-celecoxib","indication":"Colorectal cancer (based on FOLFIRI standard use with celecoxib as adjunctive agent)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Quadruple therapy","genericName":"Quadruple therapy","slug":"quadruple-therapy","indication":"Chronic hepatitis C virus (HCV) infection","status":"marketed"},{"name":"Metronidazole(MTZ)","genericName":"Metronidazole(MTZ)","slug":"metronidazole-mtz","indication":"Anaerobic bacterial infections","status":"phase_3"},{"name":"Sofosbuvir and Daklatasuvir","genericName":"Sofosbuvir and Daklatasuvir","slug":"sofosbuvir-and-daklatasuvir","indication":"Chronic hepatitis C virus infection","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"nonselective beta blocker","genericName":"nonselective beta blocker","slug":"nonselective-beta-blocker","indication":"Hypertension","status":"phase_3"},{"name":"cardio-selective beta blocker group","genericName":"cardio-selective beta blocker group","slug":"cardio-selective-beta-blocker-group","indication":"Hypertension","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Nucleo CMP Forte","genericName":"Nucleo CMP Forte","slug":"nucleo-cmp-forte","indication":"Immune system support and enhancement","status":"phase_3"}]}],"pipeline":[{"name":"FOLFERI","genericName":"FOLFERI","slug":"folferi","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Folfox with avastin","genericName":"Folfox with avastin","slug":"folfox-with-avastin","phase":"phase_3","mechanism":"FOLFOX chemotherapy combined with bevacizumab (Avastin) kills cancer cells through DNA damage while blocking tumor blood vessel formation.","indications":["Metastatic colorectal cancer","Advanced non-small cell lung cancer (in some regimens)"],"catalyst":""},{"name":"Quadruple therapy","genericName":"Quadruple therapy","slug":"quadruple-therapy","phase":"marketed","mechanism":"Quadruple therapy combines four antiviral agents to simultaneously target multiple stages of viral replication and host factors.","indications":["Chronic hepatitis C virus (HCV) infection"],"catalyst":""},{"name":"nonselective beta blocker","genericName":"nonselective beta blocker","slug":"nonselective-beta-blocker","phase":"phase_3","mechanism":"Blocks the action of beta-adrenergic receptors, leading to decreased heart rate and blood pressure.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"CHOP Plus Famotidine","genericName":"CHOP Plus Famotidine","slug":"chop-plus-famotidine","phase":"phase_3","mechanism":"CHOP Plus Famotidine combines cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP chemotherapy) with famotidine, a histamine H2-receptor antagonist, to enhance chemotherapy efficacy and reduce gastric toxicity.","indications":["Lymphoma (specific subtype under investigation in Phase 3)"],"catalyst":""},{"name":"CHOP Plus Lanzoprazole","genericName":"CHOP Plus Lanzoprazole","slug":"chop-plus-lanzoprazole","phase":"phase_3","mechanism":"CHOP Plus Lansoprazole combines chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with a proton pump inhibitor to treat Helicobacter pylori infection and gastric conditions.","indications":["Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori","Lymphoma with gastric involvement requiring gastroprotection"],"catalyst":""},{"name":"Classic treatment","genericName":"Classic treatment","slug":"classic-treatment","phase":"phase_3","mechanism":"This drug works by inhibiting the PD-1 receptor, which is involved in the immune system's response to cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Melanoma"],"catalyst":""},{"name":"Coenzyme Q","genericName":"Coenzyme Q","slug":"coenzyme-q","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Doxicycline","genericName":"Doxicycline","slug":"doxicycline","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Folferi and celecoxib","genericName":"Folferi and celecoxib","slug":"folferi-and-celecoxib","phase":"marketed","mechanism":"FOLFIRI chemotherapy combined with celecoxib inhibits tumor cell division through fluorouracil and irinotecan while reducing inflammation via COX-2 inhibition.","indications":["Colorectal cancer (based on FOLFIRI standard use with celecoxib as adjunctive agent)"],"catalyst":""},{"name":"Metronidazole(MTZ)","genericName":"Metronidazole(MTZ)","slug":"metronidazole-mtz","phase":"phase_3","mechanism":"Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced inside microbial cells.","indications":["Anaerobic bacterial infections","Trichomoniasis (Trichomonas vaginalis infection)","Amebiasis (Entamoeba histolytica infection)","Giardiasis (Giardia lamblia infection)","Bacterial vaginosis"],"catalyst":""},{"name":"Nigetella salivata","genericName":"Nigetella salivata","slug":"nigetella-salivata","phase":"phase_3","mechanism":"Nigetella salivata's mechanism of action is not well-documented.","indications":[],"catalyst":""},{"name":"Nucleo CMP Forte","genericName":"Nucleo CMP Forte","slug":"nucleo-cmp-forte","phase":"phase_3","mechanism":"Nucleo CMP Forte is a nucleotide-based supplement designed to support cellular energy metabolism and immune function through provision of cytidine monophosphate and related nucleotide precursors.","indications":["Immune system support and enhancement","Cellular energy metabolism support"],"catalyst":""},{"name":"Pantoprazole high dose","genericName":"Pantoprazole high dose","slug":"pantoprazole-high-dose","phase":"phase_3","mechanism":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Severe acid-related conditions requiring high-dose therapy"],"catalyst":""},{"name":"Pantoprazole low dose","genericName":"Pantoprazole low dose","slug":"pantoprazole-low-dose","phase":"phase_3","mechanism":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related gastrointestinal disorders"],"catalyst":""},{"name":"Sofosbuvir and Daklatasuvir","genericName":"Sofosbuvir and Daklatasuvir","slug":"sofosbuvir-and-daklatasuvir","phase":"phase_3","mechanism":"Sofosbuvir and Daklatasuvir work together to inhibit the HCV NS5B RNA-dependent RNA polymerase and NS5A protein, respectively, to treat hepatitis C virus infection.","indications":["Chronic hepatitis C virus infection","Hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection"],"catalyst":""},{"name":"Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir","genericName":"Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir","slug":"sofosbuvir-and-ledipasvir-or-sofosbuvir-and-daklatasuvir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cardio-selective beta blocker group","genericName":"cardio-selective beta blocker group","slug":"cardio-selective-beta-blocker-group","phase":"phase_3","mechanism":"Blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure.","indications":["Hypertension","Angina pectoris"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1IbjJCQU93VmJ2SGlDdVQ0Q3pYeU4tRVBNZFlzdlZpS0tIX1JkbzdYdmY1bTFFekVYV0RZWjNNM3NFOGVwc3BHamdncmd5Rks4LW11WG9uSVlEVWJWY2lN?oc=5","date":"2021-04-15","type":"trial","source":"Nature","summary":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials - Nature","headline":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis","sentiment":"positive"}],"patents":[],"drugCount":18,"phaseCounts":{"marketed":5,"phase_3":13},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}